Announcement PDF ABN 16 165 160 841 +61 (0) 3 9123 1140 | info@ampliatx.com Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 9 JANUARY 2026 ASX RELEASE ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM HIGHLIGHTS • Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer Symposium • Updated data analysis continues to show that Narmafotinib combination compares favourably with gemcitabine and Abraxane combination alone. Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce that interim data from the ongoing ACCENT trial in metastatic pancreatic cancer was showcased in a poster presentation on Friday 9 January (US time) at the American Society for Clinical Oncology: Gastrointestinal Cancer Symposium (ASCO GI) by Chief Medical Officer, Dr Jason Lickliter. The ACCENT trial is Amplia’s lead clinical program, assessing the efficacy of the company’s leading FAK inhibitor, narmafotinib, in combination with standard chemotherapy, for patients with advanced pancreatic cancer. The poster shares data that highlight both the effectiveness and safety of narmafotinib, showing promise for improving treatment results in patients with pancreatic cancer. Key points from the poster are: • The updated progression-free survival (PFS) is 7.7 months, compared to 5.5 months for Gemcitabine and Abraxane alone1 • The overall response rate (ORR) is 35%; this increases to 42% when including unconfirmed responses • Narmafotinib continues to be well tolerated by patients with the adverse effect profile of the narmafotinib – chemotherapy combination similar to chemotherapy alone A copy of the poster is included with this announcement. Dr Chris Burns, CEO of Amplia, commented, "We are pleased to present our research findings to clinicians and scientists at this conference, one of the world’s premier pancreatic cancer meetings. Presenting at ASCO GI positions Amplia among leading biotechnology and pharmaceutical companies internationally and underscores the company's exciting progress in the development of narmafotinib in pancreatic cancer." 1 New England Journal of Medicine 2013, 369, 1691 – 703 The company wishes to thank all investigators, collaborators, and patients involved in these studies. This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics. Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com U.S. Contact: Robert Giordano rjgiordano@ggrouplifesciences.com +1 917 327 3938 Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 U.S. Media: media@ampliatx.com About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn. About Narmafotinib Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumors. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the ACCENT trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has already achieved its primary endpoint in achieving a confirmed response rate of 35%, superior to 23% reported in the benchmark MPACT study for gemcitabine and Abraxane alone. An interim median PFS of 7.6 months has also been reported. A second trial – AMPLICITY – has recently opened and is being run under an IND at sites in Australia and the US, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients. Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer (ACCENT Trial): Phase 2a results Nick Pavlakis1, Sumitra Ananda2, Howard Chan3, Marion Harris4, Warren Joubert5, Jin Won Kim6, Choong-kun Lee7, Woo-Jin Lee8, Lara Lipton9, Adnan Nagrial10, Do-Youn Oh11, Joon Oh Park12, Terrie-Anne Cock13, Sarah Kinkel13, Nicole Kruger13, Christopher J. Burns13, Jason Lickliter13. 1GenesisCare, Sydney Australia; 2Epworth Cancer Services Clinical Institute Melbourne, Australia; 3Calvary Mater Hospital, Newcastle, Australia; 4Monash Medical Centre Melbourne, Australia; 5Greenslopes Oncology Brisbane, Australia; 6Seoul National University Hospital, Bundang, Korea; 7Yonsei University Health System, Seoul, Korea; 8National Cancer Center, Seoul, Korea; 9Sunshine Hospital, Melbourne, Australia; 10Westmead Cancer Care Centre, Sydney Australia; 11Seoul National University Hospital, Seoul, Korea; 12Samsung Medical Center, Seoul, Korea; 13Amplia Therapeutics, Melbourne, Australia. Narmafotinib (AMP945) is a potent, selective and orally bioavailable inhibitor of focal adhesion kinase (FAK). FAK is a non-receptor tyrosine kinase that acts through key signaling pathways to mediate communication between cells and their environment to regulate normal cellular stress responses1. Aberrant FAK signaling has been implicated in cancer progression via its role in tumor growth, migration and chemoresistance, as well as immunosuppression and tumor fibrosis2-4. FAK is frequently overexpressed in a variety of cancers, including pancreatic cancer (PCa)4, a highly fibrotic and aggressive malignancy with a poor 5-year survival rate5, in which high FAK expression correlates with poor prognosis6,7. Narmafotinib 7. Jiang H, et al. Nat Med. 2016;22(8):851-860. 8.Von Hoff DD, et al. N Engl J Med. 2013 Oct 31;369(18):1691-703 9.Wainberg , et al. Lancet. 2023 Oct 7;402(10409):1272-1281. 1.Lim ST, et al. Mol Cell. 2008 Jan 18;29(1):9-22. 2. Sulzmaier FJ, et al. Nat Rev Cancer. 2014 Sep;14(9):598-610. 3. Dawson JC, et al. Nat Rev Cancer. 2021 May;21(5):313-324. 4. Zhang Z, et al. Front Cell Dev Biol. 2022 Nov 2;10:1040311. 5. Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin 2023; 73, 17-48. 6. Zaghdoudi S, et al. EMBO Mol Med. 2020;12(11):e12010. ACCENT Trial Phase 2a results Narmafotinib combined with Gem/NabP was associated with manageable toxicity and the P2a study met its primary efficacy endpoint. Amplia has initiated (Q2 2025) a Phase 1b/2a study to investigate narmafotinib in combination with modified FOLFIRINOX in pancreatic cancer patients (AMP945-PC-202) Jason Lickliter, Amplia Therapeutics Email: jason@ampliatx.com Website: www.ampliatx.com Narmafotinib is safe and well tolerated in combination with Gem/NabP ACCENT Study Overview Progression Free Survival (PFS) • PFS determined using all ACCENT patients on 400mg narmafotinib (Part A and Part B) • Median PFS 7.7 months • Compares favourably with Gem/NabP alone (5.5 months)8 and FOLFIRINOX (6.4 months)9 All ACCENT patients @ 400mg (n = 64) PIVOTAL STUDY Narmafotinib +Gem/NabP (ACCENT N=55) Gem/ NabP (8MPACT; N=421) Gem/ NabP (9NAPOLI 3; N=379) Adverse Event (AE) Grade ≥ 3 Neutropenia 38.2% 38% 39% Anemia 9.1% 13% 18% Diarrhea 5.5% 6% 5% Peripheral neuropathy 3.6% 17% 6% Vomiting 3.6% NR 2% Febrile Neutropenia 5.5% 3% NR Thrombocytopenia NR 13% NR Fatigue NR 17% 5% Hypokalemia NR NR 4% Nausea 3.6% NR 3% NR: not reported Narmafotinib-related AEs in ≥ 5% of patients, n (%) Severity of Treatment- Related AEs Any grade n (%) Grade ≥ 3 n (%) Nausea 16 (29.1) 2 (3.6) Diarrhea 9 (16.4) 2 (3.6) Vomiting 8 (14.5) 1 (1.8) Fatigue 6 (10.9) 0 Gastroesophageal reflux disease 4 (7.3) 0 Constipation 3 (5.5) 0 ACCENT trial (NCT05355298): Phase 1b/2a, open label study of the pharmacokinetics, safety and efficacy of narmafotinib in combination with gemcitabine and nab- paclitaxel as first-line therapy in patients with metastatic pancreatic cancer. Part A (Phase 1b): Narmafotinib dose escalation (100, 200 and 400 mg) was completed, and the recommended phase 2 dose (400mg) was identified. Part B (Phase 2a): Gem (1000 mg/m2) and NabP (125 mg/m2) were given on days 1, 8 and 15 of a conventional 28-day cycle. Patients also received narmafotinib (400 mg, p.o. mane) priming on days -8 to -2 of cycle 1 and then combined as 4-day pulses beginning on days 3, 10 and 24 of each 28-day chemotherapy cycle. The primary endpoint was investigator assessed objective response rate (ORR) by RECIST v1.1. Key secondary endpoints included adverse events (AEs, using NCI CTCAEv5.0), progression free survival (PFS) and overall survival (OS). The preliminary results presented here include safety (cut-off 20th July 2025) and efficacy data (cut-off 25th Sept 2025). Only 2 patients (3.6%) had narmafotinib withdrawn due to a related AE. Toxicity was overall similar to that reported for chemotherapy alone. Tumor imaging assessments were conducted every 2 months and evaluated using RECIST 1.1. All patients planned for the ACCENT Phase 2a study were recruited between 16th Jan 2024 and 17th Feb 2025 in Australia and South Korea. Demographics Patient # (total study) 55 Geographic area (%) Australia (44%) / Korea (56%) Female (%) 49% Age median (min-max) 64 (37 - 87) ECOG PS 0 17 (31%) ECOG PS 1 38 (69%) Ethnic background Caucasian 21 (38%) Asian 33 (60%) Australian Aborigine / Torres Strait Islander 1 (2%) Arrow indicates patients still on trial. pCR indicates pathological complete response. Only patients with a valid post- baseline RECIST assessment scan are shown. Partial response (PR) ≤-30% Unconfirmed partial response indicated by light blue PD SD PR CR pCR Partial response (PR) ≤-30% Progressive disease (PD) ≥20% Encouraging antitumor activity with rapid and sustained tumor reduction 19 confirmed responses observed to date: including,  1 confirmed complete response and 1 pathological complete response 7 patients on study > 1 year: range: 21 – 548 days, with 9 patients still on trial ACCENT Trial* (n) % 8MPACT Trial CR (1) 2% 0.2% PR (18) 33% 23% SD (23) 42% 27% PD (7) 13% 20% NE (6) 11% 30% ORR (CR+PR)† (19) 35% 23% DCR (CR+PR+SD) (42) 76% 50% *Numbers calculated on the ITT population of n=55 † Unconfirmed ORR: (23) 42%